Home Cart Sign in  
Chemical Structure| 654073-32-2 Chemical Structure| 654073-32-2

Structure of 654073-32-2

Chemical Structure| 654073-32-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 654073-32-2 ]

CAS No. :654073-32-2
Formula : C3H8N2O2S
M.W : 136.17
SMILES Code : O=S(N1CCC1)(N)=O
MDL No. :MFCD18806627
InChI Key :STIUWSWFXIBBKI-UHFFFAOYSA-N
Pubchem ID :45080566

Safety of [ 654073-32-2 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 654073-32-2 ] Show Less

Physicochemical Properties

Num. heavy atoms 8
Num. arom. heavy atoms 0
Fraction Csp3 1.0
Num. rotatable bonds 1
Num. H-bond acceptors 4.0
Num. H-bond donors 1.0
Molar Refractivity 32.9
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

71.78 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

0.48
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

-1.03
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

-0.4
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

-0.98
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-1.17
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

-0.62

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

0.03
Solubility 146.0 mg/ml ; 1.07 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Highly soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

0.01
Solubility 139.0 mg/ml ; 1.02 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Highly soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

0.42
Solubility 357.0 mg/ml ; 2.62 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-7.86 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

2.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.81

Application In Synthesis of [ 654073-32-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 654073-32-2 ]

[ 654073-32-2 ] Synthesis Path-Upstream   1~3

  • 1
  • [ 1271835-78-9 ]
  • [ 654073-32-2 ]
YieldReaction ConditionsOperation in experiment
58% With 2,5-dihydrotoluene; palladium(II) hydroxide In methanol at 60℃; Inert atmosphere A mixture of palladium hydroxide 20percent (350 mg), benzyl(azetidin-1-ylsulfonyl)carbamate (Preparation 20, 1 .49 g, 5.5 mmol) and 1-methyl-1,4-cyclohexadiene (10.7 g, 0.1 1 mol) in methanol (35 ml_) was stirred and heated at 60 °C overnight under nitrogen. The reaction mixture was cooled to room temperature, passed through a pad of celite and concentrated in vacuo to afford the title compound (437 mg, 58percent) as a solid. 1 H NMR (400 MHz, CD3OD) δ ppm 2.15 (pent, 2H), 3.78 (t, 4H). LCMS no mass ion observed
58% With 2,5-dihydrotoluene; palladium(II) hydroxide In methanol at 60℃; Inert atmosphere A mixture of palladium hydroxide 20percent (350 mg), benzyl (azetidin-l -ylsulfonyl)carbamate (Preparation 47, 1 .49 g, 5.5 mmol) and 1 -methyl-1 ,4-cyclohexadiene (10.7 g, 0.1 1 mol) in methanol (35 mL) was stirred and heated at 60 °C overnight under nitrogen. The reaction mixture was cooled to room temperature, passed through a pad of celite and concentrated in vacuo to afford the title compound (437 mg, 58percent) as a solid. 1 H NMR (400 MHz, CD3OD) δ ppm 2.15 (pent, 2H), 3.78 (t, 4H). MS m/z no mass ion observed
References: [1] Patent: WO2013/88315, 2013, A1, . Location in patent: Page/Page column 75.
[2] Patent: WO2013/102826, 2013, A1, . Location in patent: Page/Page column 91.
  • 2
  • [ 503-29-7 ]
  • [ 654073-32-2 ]
References: [1] Patent: WO2004/11443, 2004, A1, . Location in patent: Page 74-75.
  • 3
  • [ 503-29-7 ]
  • [ 96042-30-7 ]
  • [ 654073-32-2 ]
References: [1] Patent: US2005/267018, 2005, A1, .
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 654073-32-2 ]

Amines

Chemical Structure| 147962-41-2

A118075 [147962-41-2]

N-Propylsulfamide

Similarity: 0.79

Chemical Structure| 1393813-41-6

A111435 [1393813-41-6]

Potassium (N-propylsulfamoyl)amide

Similarity: 0.76

Chemical Structure| 3984-14-3

A108448 [3984-14-3]

N,N-Dimethylsulfamide

Similarity: 0.67

Sulfamides

Chemical Structure| 137830-77-4

A183771 [137830-77-4]

2-Methyl-1,2,6-thiadiazinane 1,1-dioxide

Similarity: 0.89

Chemical Structure| 147962-41-2

A118075 [147962-41-2]

N-Propylsulfamide

Similarity: 0.79

Chemical Structure| 67104-97-6

A155249 [67104-97-6]

2-Methyl-1,2,5-thiadiazolidine 1,1-dioxide

Similarity: 0.78

Chemical Structure| 1393813-41-6

A111435 [1393813-41-6]

Potassium (N-propylsulfamoyl)amide

Similarity: 0.76

Chemical Structure| 3984-14-3

A108448 [3984-14-3]

N,N-Dimethylsulfamide

Similarity: 0.67